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ABSTRACT 
 
Endoplasmic reticulum aminopeptidase 1 
(ERAP1) trims antigenic peptide precursors to 
generate mature antigenic peptides for 
presentation by major histocompatibility 
complex class I (MHCI) molecules and regulates 
adaptive immune responses. ERAP1 has been 
proposed to trim peptide precursors both in 
solution and in pre-formed MHCI–peptide 
complexes, but which mode is more relevant to 
its biological function remains controversial. 
Here, we compared ERAP1-mediated trimming 
of antigenic peptide precursors in solution or 
when bound to three MHCI alleles, HLA–B*58, 
HLA–B*08 and HLA–A*02. For all MHCI–
peptide combinations, peptide binding onto 
MHCI protected against ERAP1–mediated 
trimming. In only a single MHCI-peptide 
combination, trimming of an HLA-B*08–bound 
12mer progressed at a considerable rate, albeit 
still slower than in solution. Results from 
thermodynamic, kinetic and computational 
analyses suggested that this 12mer is highly 
labile and that apparent on–MHC trimming rates 
are always slower than that of MHCI–peptide 
dissociation. Both ERAP2 and leucine 
aminopeptidase, an enzyme unrelated to antigen 
processing, could trim this labile peptide from 
pre-formed MHCI complexes as efficiently as 
ERAP1. A pseudopeptide analogue with high 
affinity for both HLA–B*08 and the ERAP1 
active site could not promote the formation of a 
ternary ERAP1–MHCI–peptide complex. 
Similarly, no interactions between ERAP1 and 
purified peptide loading complex (PLC) were 
detected in the absence or presence of a 
pseudopeptide trap. We conclude that MHCI 
binding protects peptides from ERAP1 
degradation and that trimming in solution, along 
with the dynamic nature of peptide binding to 
MHCI, are sufficient to explain ERAP1 
processing of antigenic peptide precursors. 
 
 Cytotoxic T-lymphocytes recognize 
infected or otherwise aberrant cells through 
specialized receptors that interact with ligands 
on the surface of somatic cells. The T-cell 
receptor can interact with the Major 
Histocompatibility Complex class I molecules 
(MHCI) that are located on the cell surface of all 
somatic cells and carry bound small peptides, 
called antigenic peptides (1). These peptides are 
generated intracellularly from the proteolytic 
degradation of antigenic proteins. During the 
latter parts of this pathway, N-terminally 
extended precursors of antigenic peptides are 
trimmed by ER-resident aminopeptidases 
ERAP1 and ERAP2 (2). Since its initial 
discovery, ERAP1, has emerged as an important 
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component of the antigenic peptide generation 
pathway (3,4). Accordingly, ERAP1 activity can 
influence the peptide cargo of MHCI molecules 
and regulate the immunogenicity of cells as 
demonstrated by several genetic knockdown 
studies (5,6). Furthermore, ERAP1 has been 
shown to be able to regulate the immunogenicity 
of cancer cells, making it a potential target for 
cancer immunotherapy (7-9). ERAP1 is 
polymorphic and several coding single 
nucleotide polymorphisms in its gene have been 
associated with predisposition to major human 
diseases, primarily related to inflammatory 
autoimmunity, often in epistasis with particular 
HLA-alleles (10-12).  
The role of ERAP1 in disease is believed to, 
at least in part, arise from its effects in shaping 
the cellular immunopeptidome, that is, the sum 
of peptides that are presented by MHCI (13). 
Several studies have described the effects of 
altered ERAP1 activity (either due to genetic 
manipulation or natural polymorphic variation) 
on the immunopeptidome of cell lines and in vivo 
models. ERAP1 has been found to influence a 
significant component of the immunopeptidome 
by altering both sequence and length of 
presented peptides (14-17). These effects are 
generally interpreted to be the result of its 
aminopeptidase activity. In vitro analysis has 
revealed that ERAP1 has some unusual 
molecular properties compared to other 
aminopeptidases, which appear to fit well to this 
biological role. Specifically, peptide trimming 
appears to be affected by peptide sequence 
throughout the whole peptide and not just by the 
vicinity of the N-terminus where hydrolysis 
occurs (18). Furthermore, ERAP1 prefers to trim 
longer peptides over shorter ones, with the 
threshold being around 9 amino acids, the 
optimal length for binding onto MHCI (19,20). 
The latter preference has led to the “molecular 
ruler” mechanism proposal by Goldberg and 
colleagues in 2005 (21). All of those preferences 
are affected by polymorphic variation, possibly 
explaining the biological effects of ERAP1 
haplotypes (22). 
Apart from the well characterized activity of 
ERAP1 to trim peptides in solution, an 
alternative mechanism has been proposed that 
offers a different vantage point on the generation 
of the immunopeptidome. According to this, 
ERAP1 can trim peptides while they are bound 
onto the MHCI. This mechanism has been 
supported by in vitro digestions using a 
covalently linked leucine-zipper dimer of 
ERAP1-ERAP2 (23) in addition to evidence 
from cellular assays (24,25). The known ERAP1 
crystal structures to date are largely 
incompatible with this mode of action due to 
steric hindrance that would make it difficult for 
ERAP1 to access the N-terminus of an MHCI-
bound peptide, which would be possible only for 
very long peptides, over 16 amino acids, even for 
the open ERAP1 conformer (19,26). However, it 
is possible that ERAP1 conformations more 
open than those observed in structural studies to 
date might permit transient interactions with 
MHCI-bound peptides (27). Furthermore, as 
demonstrated in the recently solved cryo-EM 
structure of the Peptide Loading Complex (PLC, 
a multi-protein machinery that ensures proper 
loading of peptides onto MHCI), chaperone 
binding onto MHCI would make it difficult for 
ERAP1 to approach the MHCI, although ERAP1 
interaction is not completely precluded by steric 
considerations (28,29). In contrast, MHCI have 
been shown to protect peptides from degradation 
by ERAP1 (30). Partial dissociation of the 
MHCI-bound peptide in conjunction with 
conformational rearrangements of ERAP1 
towards more open states has been proposed as a 
mechanistic requirement to overcome these 
limitations, but direct experimental tests are 
lacking (27,31). Understanding the mode of 
ERAP1 peptide trimming is important because it 
alters our understanding of ERAP1’s functional 
role in shaping the immunopeptidome in vivo. 
Solution trimming assumes that peptide 
selectivity arises from ERAP1/peptide 
interactions, while onto-MHCI trimming shifts 
at least part of the specificity to MHCI/peptide 
or ERAP1/MHCI/peptide interactions (26). 
To provide insight on the mechanism of 
ERAP1 trimming of peptide precursors we 
analyzed the ability of ERAP1 to trim several N-
terminally extended antigenic peptide precursors 
in solution and in complex with the MHCI alleles 
HLA-B*58:01, HLA-B*08 and HLA-A*02. 
MHCI-peptide complexes with sequences 
extending from the N-terminal side of the 
binding groove and also MHCI-peptide 
complexes with internal bulges were examined. 
Combination of enzymatic, biochemical, and 
biophysical analyses suggest that while stably 
bound MHCI peptides are highly protected from 
ERAP1 activity, only the highly labile 
MHCI/peptide complexes can be apparently 
processed by ERAP1. This phenomenon is 
however more likely determined by fast 
dissociation of the peptide from the MHCI 
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followed by ERAP1 processing in solution 
rather than by formation of an obligate ternary 
ERAP1/peptide/MHCI complex.  
 
Results 
 
Trimming of extended peptide variants of the 
TW10 epitope bound to HLA-B*58 
 Trimming by an aminopeptidase like 
ERAP1 requires access to a free N-terminus of 
the peptide substrate. The vast majority of 
MHCI/peptide crystal structures however, 
feature peptides that are 8-10 amino acids long 
and have the N-terminus of the peptide making 
specific interactions within the MHCI binding 
groove, interactions that are important for 
maintaining high binding affinity (32). One 
notable exception is the HIV Gag epitope TW10 
(sequence TSTLQEQIGW) bound onto HLA-
B*58:01 (henceforth referred to as B58), in 
which a recent crystal structure has shown that 
its N-terminus protrudes from the peptide 
binding groove (33). This configuration would 
allow N-terminal extension away from the 
MHCI and therefore such peptides could be 
substrates of ERAP1. To test this, we prepared 
complexes of B58 with TW10 and a series of N-
terminally extended peptides, up to 25 amino 
acids long, as shown in Figure 1 (also refer to 
Supporting Figure 1 for a representative 
chromatogram after in vitro folding). All 
peptides carry an N-terminal leucine, which is an 
optimal residue for trimming by ERAP1 and 
which facilitates monitoring of the trimming 
reaction by HPLC. In all cases, we were able to 
purify B58/peptide complexes and use them for 
trimming reactions. We compared trimming of 
the same molar concentration of peptide and 
B58/peptide complex, using two different 
enzyme concentrations. In all cases, we observed 
rapid degradation of the peptide in solution by 
ERAP1, but either very limited or no 
degradation at all of B58-bound peptide (Figure 
1 and Supporting Figure 2). A notable exception 
was the 25mer peptide L-GW24 which was a 
poor substrate in solution (consistent with the 
known length dependence of ERAP1 activity 
(21)) and was not processed at all when bound 
onto B58. We thus conclude that most N-
extended peptides based on the TW10 sequence 
are good ERAP1 substrates in solution, but all 
are very poor substrates when bound onto B58. 
This suggests that although the N-terminus of 
these peptides is exposed to the solvent when 
they are bound onto B58, ERAP1 is not able to 
form a catalytically productive complex. 
 
Trimming of peptides bound on HLA-A02 in a 
bulged conformation 
 The majority of elongated peptides that 
are stably bound onto MHCI bind with a bulged 
conformation, as revealed by examining crystal 
structures deposited in the PDB database. In this 
conformation the peptide N- and C-termini make 
atomic interactions with the MHCI while the 
middle part of the peptide “bulges out” to allow 
the peptide to be accommodated within the 
limited length of the MHCI binding groove (34). 
Two recent crystal structures of HLA-A*02 with 
a 15mer and a 12mer peptide epitope highlight 
this binding mode (35,36). Since ERAP1 
trimming has been implicated in the destruction 
of antigenic epitopes (3), we investigated 
whether ERAP1 can trim these two peptides 
(FK12 with the sequence FVLELEPEWTVK 
and FM15 with the sequence 
FLNKDLEVDGHFVTM) in solution and while 
bound onto HLA-A*02:01 (henceforth referred 
to as A02). Trimming was followed by MALDI-
MS, an experimental approach that has the added 
benefit of being able to follow the generation of 
multiple trimming products. FK12 was a 
moderate substrate of ERAP1 in solution and 
was trimmed down to the 11mer with a half-life 
of about 2 h (Figure 2A). Strikingly, when bound 
onto A02, FK12 was processed very poorly, with 
less than 5% trimmed after 2 h (Figure 2D). In 
contrast, FM15, was a good substrate of ERAP1, 
leading to 90% conversion to the 12mer product 
after 30 min (Figure 2B,C). When in a pre-
formed complex with A02, however, FM15 was 
processed much slower with an estimated half-
life of about 3 h (Figure 2E,F). We thus conclude 
that similar to the results for B58, extended 
peptide epitopes bound onto A02 are protected 
by the activity of ERAP1 compared to trimming 
in solution.  
 
Trimming of extended peptides bound on 
HLA-B*08:01 
 Considering that our results using B58 
and A02 come in contrast with recent reports of 
ERAP1 trimming peptides while bound onto 
HLA-B*08:01 (23,37) (henceforth referred to as 
B08), we decided to examine if this property is 
limited to the interaction of ERAP1 with this 
particular allele. Folding B08 with two 12mers 
(sequence LSILLKHKKAAL, from nuclear 
factor NF-kappa-B p105 subunit, henceforth 
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called LL12 and sequence ARAALRSRYWAI, 
from nucleoprotein of influenza A virus 
henceforth called AI12) was successful, based 
on size exclusion chromatography followed by 
SDS-PAGE and MALDI-MS (Supporting 
Figure 3). In solution, LL12 was found to be an 
exceptionally good substrate for ERAP1 and was 
converted to the 11mer with a half-life of 19±5 
min (Figure 3, panel A). Similarly, LL12 was 
found to be a good substrate for the homologous 
aminopeptidase ERAP2, an enzyme also 
described to play roles in antigen processing 
(38). In sharp contrast, LL12 in pre-formed 
purified complex with B08, was completely 
resistant to trimming by either ERAP1 or 
ERAP2, even when the enzyme was used at 
concentrations up to 100 nM (Figure 3, panel B). 
We conclude that in accordance to the results 
obtained for B58 and A02, elongated peptide 
LL12 binding onto B08 can fully protect it from 
trimming by ERAP1. 
 Trimming of the peptide AI12 by 
ERAP1 in solution was found to be very efficient 
and dependent on enzyme concentration 
(ranging from 2 nM to 100 nM as shown in 
Figure 4, panel A). Under most conditions, 
trimming by ERAP1 led to the accumulation of 
the 9mer antigenic epitope ALRSRYWAI 
(henceforth called AI9, Figure 4, panel A, top 
row). At the highest concentration of ERAP1 
(100 nM) however, the 12mer peptide was fully 
consumed within 5 min and even the 9mer 
epitope was trimmed down to shorter peptides 
(Figure 4, panel B). These observations are 
consistent with the dual nature of ERAP1 in 
being both a producer and a destroyer of 
antigenic epitopes (3). The AI12 peptide was 
also found to be a good substrate of the 
homologous aminopeptidase ERAP2 and so was 
the case for leucine aminopeptidase (LAP), a 
cytosolic metabolic enzyme not directly 
associated with antigen processing (39). The 
effect of LAP and ERAP2 however, was the 
accumulation of smaller peptides, notably the 
6mer, which is consistent with the proposed role 
of ERAP2 in destroying antigenic epitopes (40).  
 Strikingly, when analyzing the reaction 
of pre-formed complexes of AI12 with HLA-
B08, we observed significant trimming by 
ERAP1, which was dependent on the enzyme 
concentration (Figure 4A, bottom row and 
Supporting Figure 4). Trimming rates of the 
12mer though appeared to plateau at 100 nM of 
enzyme and were always much lower compared 
to trimming in solution (Figure 4C). 
Furthermore, trimming of AI12/B08 by ERAP1 
appeared to be less efficient in generating the 
mature epitope (9mer) than trimming in solution. 
Still, this was the first time in our analysis that 
we recorded significant trimming of a pre-
formed MHCI/peptide complex and this appears 
to support the notion that the interaction of 
ERAP1 with B08 is different when compared to 
A02 and B58. This phenomenon however was 
not unique to ERAP1 as both ERAP2 and LAP 
were able to trim the preformed AI12/B08 
complex at rates comparable to ERAP1.  
 To better understand the effects of 
ERAP1 on B08 complexes, we analyzed the 
behavior of those complexes by native-PAGE 
(Figure 4B and Supporting Figure 5). The 
various B08 complexes migrate differently in 
native-PAGE depending on the total charge 
carried by different peptides, allowing us to 
follow the conversion from one complex to 
another over time (Supporting Figure 5A). 
Complexes with the 9mer epitope EI9 and the 
12mer peptide LL12 were stable upon 
incubation with ERAP1 (Figure 4B, left and 
Supporting Figure 5). In contrast, incubation of 
the complex B08/AI12 with ERAP1 or ERAP2 
resulted in the down-shift of the protein band, 
corresponding to complexes of B08 with smaller 
peptides (Figure 4B middle and right and 
Supporting Figure 5). The rate of change in 
migration was dependent on the amount of 
enzyme added. Adding the epitope AI9 in the 
complex allowed us to measure the rate of 
exchange of each 12mer for the 9mer epitope 
(Supporting Figure 5J-K). Using densitometric 
analysis we calculated the rate of conversion for 
each reaction (Figure 4D). Similar to the results 
from the MALDI-MS analysis, both ERAP1 and 
ERAP2 were able to convert the initial 12mer 
complex to MHC complexes with smaller 
peptides, displaying kinetics that plateaued 
around 100 nM ERAP1. In all cases, the 
exchange of AI12 for AI9 was faster. We 
conclude that although ERAP1 appears to be 
able to trim the 12mer peptide AI12 in pre-
formed B08/AI12 complexes, this reaction 
appears to be slower than the dissociation rate of 
AI12 from B08 when in competition with the 
AI9 epitope.  
 
Characterization of thermodynamic and 
kinetic stability of B08 complexes 
The sharp difference between the 
behavior of the two B08 complexes (with the 
AI12 versus the LL12 peptide) in regards to 
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on A
pril 13, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 5 
trimming by ERAP1, prompted us to 
characterize further their thermodynamic and 
kinetic stability. While both 12mers formed 
complexes with B08 that were sufficiently stable 
to allow characterization (Supporting Figure 3), 
biophysical analysis suggested that the 
complexes are quite distinct in terms of 
thermodynamic and kinetic stability (Figure 5A 
and Supporting Figure 6, Supporting Tables 1,2). 
Using the Differential Scanning Fluorimetry 
Assay (DSF) (41), the B08/LL12 complex 
displayed a Tm value of 57.7±0.4 °C. In contrast, 
the B08/AI12 complex, was markedly less stable 
with Tm value of 47.8±2.3 °C. For comparison, 
analysis of B08 in complex with the antigenic 
peptide ELRSRYWAI (EI9) and its analogue 
ALRSRYWAI (AI9) indicated Tm values of 
66.1±0.3 °C and 63.3±0.8 °C, respectively. 
Measurements of their thermodynamic stability 
using circular dichroism gave similar 
comparative results. Additionally, kinetic 
stability as judged by exchange of the peptide 
with excess SYPRO-Orange dye was very 
different for the two peptides (Figure 5, panels 
B-G). The B08/LL12 complex was found to be 
reasonably stable with a half-life of 362 min 
which is comparable to the half-lives of 891±92 
min and 1056±152 min that were determined for 
the 9mer antigenic peptide complexes B08/EI9 
and B08/AI9, respectively. In contrast, 
B08/AI12 was kinetically labile with an 
estimated half-life of 9±1 minute (Figure 5, 
panels E and F). These results were in good 
agreement with native-PAGE analysis of folded 
complexes in competition with excess free 
epitope AI9, which showed half-lives of 317 min 
for B08/LL12 and 18 min for B08/AI12 
(Supporting Figure 5J-K). Taken together, these 
results suggest that while both N-terminally 
extended peptides can form sufficiently stable 
ternary complexes with B08 to allow their 
purification, AI12 forms a significantly more 
kinetically labile and thermodynamically 
unstable complex compared to LL12. 
 
Molecular dynamics of MHCI-peptide 
complexes 
To gain atomic-level insight into the role 
of the N-terminus extension for the less stable 
B08/AI12 complex as compared to the more 
stable B08/LL12, we carried out a comparative 
molecular dynamics (MD) study. For reference, 
we also performed MD simulations for the 
complexes of the 9mer antigenic peptides EI9 
and AI9 using the recent X-ray crystal structure 
of B08 complex with EI9 (PDB ID: 5WMQ, 
resolved at 1.4 Å) (42). The modeling of the N-
terminally extended peptides was based on the 
hypothesis that the peptides would bulge out to 
favorably accommodate their N and C termini 
within the binding groove of the MHC-I, similar 
to the analyzed A02 complexes. Starting from 
AI12, we used the X-ray coordinates of residues 
P1 (E) and P4–P9 (SRYWAI) as template for the 
modeling of the 12mer peptide, so as to 
constraint the position of the N-terminus inside 
pocket A of the HLA-B08. Five models with 
variable conformations at the “bulged-out” 
region of AI12 were selected as starting 
structures for the MD simulations (Supporting 
Figure 7). These conformations were used as 
templates for the modeling of LL12, in order to 
compare the sampled conformational space of 
AI12 with LL12 with as similar initial conditions 
as possible (Supporting Figure 8). 
For the four B08/peptide systems we 
performed five MD simulations of 500-ns each, 
from which we calculated the mean atomic root-
mean-square fluctuations (RMSF) of the Cα 
atoms of the peptides, after RMS fitting of the 
trajectories with respect to the antigen-binding 
domain (Cα atoms of residues 1–180) of the 
MHCI (Figure 6). The 9mer epitope EI9 and the 
homologue AI9 peptide displayed the highest 
stability with the lowest mean RMSF values (< 
0.9 Å), followed by LL12, for which the RMSF 
values were 0.9–1.8 Å throughout the whole 
sequence (Supporting Figures 9-11). In contrast, 
AI12 exhibited very high mobility at the three N-
terminal residues (Figure 6), with progressively 
lower values towards the C-terminus of the 
peptide (Figure 6). The high flexibility of AI12 
was a result of partial dissociation of the N-
terminus from pocket A of the MHCI, while the 
five C-terminal residues (RYWAI) were as 
stable as in the 9mer peptides (Supporting Figure 
11,12). To confirm that this effect is not 
dependent on the initial conformation of the 
peptide employed, we carried out five additional 
MDs for each B08 complex with AI12 and 
LL12, starting from the conformation that 
displayed the most stable complexes in our 
simulations (designated as “sim-2” in 
Supporting Figures 9-11). In accordance with the 
first set of simulations that were initiated from 
different peptide conformations, AI12 revealed 
significantly higher mobility at the N-terminal 
residues with respect to LL12 (Supporting 
Figure 13). This observation is in good 
agreement with the results of the thermal and 
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kinetic stability measurements for the four HLA-
B08/peptide complexes (Figure 5), with the 
experimental Tm and half-life values correlating 
nicely with the trend of the mean RMSF values 
for EI9 ≈ AI9 < LL12 << AI12. Although the 
MD simulations at the microsecond timescale 
cannot be directly translated to the much longer 
timescales of the experimental measurements, 
our results suggest that the kinetic instability of 
B08/AI12 as compared to B08/LL12 is probably 
a result of the highly labile N-terminus moiety of 
AI12 that can readily detach from the MHCI 
binding groove. 
 
No evidence for a ternary ERAP1 / MHCI / 
peptide complex when using a transition-state 
analogue pseudopeptide trap 
 Transition-state analogues have been 
used as potent tools to study enzyme-substrate 
interactions. In particular, phosphinic 
pseudopeptides have been shown to be valuable 
tools for the study of ERAP1 and ERAP2 
interactions with peptide substrates since they 
are non-hydrolysable and feature high affinities 
for the active site of those aminopeptidases 
(40,43). Based on the observation that ERAP1 
appears to trim the peptide AI12 in pre-formed 
complex with B08, we wanted to test the 
possibility that ERAP1 might be forming a 
transient complex with the MHCI/peptide 
complex. To probe this putative interaction, we 
designed a phosphinic pseudopeptide based on 
the sequence of AI12. The peptide H-
AΨ[P(O)(OH)CH2]KAALRSRYWAI-OH, 
named DG078, carries the phosphinic group in 
place of the N-terminal peptide bond which is 
non-hydrolysable and is expected to bind to the 
active site of ERAP1 with high affinity as 
previously shown for other similar peptides 
(40,44). DG078 was successfully folded with 
B08 at a similar yield as AI12, and the presence 
of the peptide in the purified complex was 
confirmed by MALDI-MS (Supporting Figure 
14). Thermal stability analysis revealed a Tm 
value of 46.1±0.3 °C, which is similar to that of 
B08/AI12, indicating that the introduction of the 
phosphinic moiety did not significantly alter 
binding onto B08 (Supporting Figure 15). 
Furthermore, the dissociation rate of the peptide 
off B08 upon competition with SYPRO-Orange, 
had a half-life of 12.7 min (Figure 7A) which is 
similar to the half-life calculated for AI12 (9 
min). As expected, DG078 in solution acted as a 
potent inhibitor of ERAP1 with a calculated IC50 
value of 39 nM (Figure 7E). Given the high 
affinity of DG078 for both ERAP1 and for B08, 
we hypothesized that it may be an efficient linker 
to enhance any potential transient interactions 
between ERAP1 and B08. To investigate this, 
we analyzed B08 in complex with DG078 using 
native PAGE, either alone or pre-mixed with 
ERAP1 or ERAP2 (Figure 7B). Surprisingly, we 
were unable to detect any stable heterotrimeric 
species consisting of ERAP1/DG078/B08 
suggesting that ERAP1 cannot interact stably 
with DG078 while the peptide is bound to B08.  
Since this finding raised questions on 
how ERAP1 can appear to trim AI12 while it is 
bound onto B08, we further analyzed the 
interaction of ERAP1 with DG078 by following 
the enzymatic activity of ERAP1 (Figure 7C). 
As expected, mixing 500 nM of DG078 with 10 
nM ERAP1, greatly reduced ERAP1’s ability to 
hydrolyze the fluorigenic substrate L-AMC 
(Figure 7C). Interestingly, using 500 nM of 
B08/DG078 had a similar effect on ERAP1 
activity, indicating that DG078, from pre-formed 
B08 complexes, could access the active site of 
ERAP1. Titrating B08/DG078 to ERAP1 
revealed a dose-dependent decrease of its 
activity, with an apparent IC50 of 167 nM, which 
is about 5-fold weaker than for the free DG078 
peptide (Figure 7E). Notably, the inhibition of 
ERAP1 by B08/DG078 showed a much smaller 
slope compared to free DG078, suggestive of a 
more complex kinetic phenomenon. Strikingly, 
these effects were not limited to ERAP1 as 500 
nM DG078 as well as B08/DG078, were able to 
inhibit LAP (Figure 7C, right). DG078 was able 
to inhibit LAP with an IC50 that was lower than 
for ERAP1 (108 nM, Figure 7E), but 
B08/DG078 inhibited LAP with a similar IC50 of 
152 nM (Figure 7E). 
In summary, our experiments suggest 
that DG078 from pre-formed complexes with 
B08 can access ERAP1’s active site, but cannot 
form stable ternary complexes. This apparent 
paradox can be reconciled by taking into account 
the fast off kinetics of DG078 from B08. It is 
therefore possible that the DG078 peptide 
dissociates from the B08/DG078 complex to 
interact with and inhibit ERAP1. It should be 
noted that because of the 50-fold excess of 
DG078/B08 complex used in those experiments 
and the high affinity of DG078 for ERAP1, even 
a minor population of dissociated DG078 from 
the B08/DG078 complex, would be sufficient to 
fully inactivate the enzymes. By extrapolation, it 
is therefore highly probable that the apparent 
trimming of AI12 while bound onto B08 is a 
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 7 
result of rapid peptide dissociation and 
subsequent solution trimming, rather than the 
formation of a ternary ERAP1/ B08/AI12 
complex.  
  
No evidence for direct molecular interactions 
between ERAP1 or ERAP2 and the Peptide 
Loading Complex 
 Peptide loading onto MHCI inside the 
ER is facilitated and regulated in cells by a multi-
protein complex called the Peptide Loading 
Complex (PLC) (45). A recently solved structure 
of the PLC revealed how all of its protein 
components cooperate in a single molecular 
entity (29). ERAP1 and ERAP2 were not found 
to be part of this complex, although transient 
interactions could not be ruled out. Since we 
found no evidence for a direct ERAP1/MHCI 
interaction we decided to investigate possible 
interactions between ERAP1 or ERAP2 with a 
pre-formed PLC. To this end, PLC was purified 
via ICP47-SBP from Raji cells and incubated for 
30 min at 4 °C bound onto streptavidin coated 
beads with 4-fold excess of ERAP1 or ERAP2 or 
a mixture of both (Figure 8A). The beads were 
then washed and bound proteins eluted and 
analyzed on SDS-PAGE (Figure 8B). All the 
components of the PLC can be visualized on the 
gel (TAP1/2, ERp57, Calreticulin, Tapasin, 
MHCI heavy chain and beta-2-microglobulin) 
after elution from the beads. However, no 
ERAP1 or ERAP2 could be detected on the 
beads, while both enzymes were found in the 
wash fraction only. This result was confirmed by 
size-exclusion chromatography (SEC) that 
indicated discrete single monodisperse peaks for 
both the PLC and ERAP1 or ERAP2, which 
were not significantly altered when the PLC and 
ERAPs were preincubated together (Figure 8C-
E). This analysis suggests that neither 
recombinant ERAP1 nor ERAP2 can form stable 
interactions with pre-formed PLC isolated from 
cells.  
 Since it is possible that ERAP1 and 
ERAP2 can form transient interactions with the 
PLC as they catalyze trimming of an MHCI-
bound peptide, we designed an N-terminally 
extended 15mer peptide trap that could stabilize 
this transient interaction. Peptide DG057 is 
based on the epitope SQFGGGSQY from the 
eukaryotic translation initiation factor 3 subunit 
D which is an optimal ligand for HLA-A03 that 
is the MHCI allele component of PLC purified 
from Raji cells (29). DG057 carries a phosphinic 
group between the first two amino acids, 
similarly to the peptide DG078 used in Figure 7, 
and should act as a non-hydrolysable, transition-
state, high-affinity inhibitor for both ERAP1 and 
ERAP2. We therefore hypothesized that this 
peptide could operate as a molecular trap that can 
stabilize a transient interaction between ERAP1 
or ERAP2 and the PLC. Indeed, DG057 was 
found to be a potent inhibitor of ERAP1 and 
ERAP2 in vitro, with an IC50 of 20 nM and 648 
nM respectively (Supporting Figure 16). As 
described before, PLC purified via ICP47-SBP 
from Raji cells was bound on streptavidin coated 
beads (Figure 8A)(29). First, either the PLC or 
ERAP1, ERAP2 or pre-mixed ERAP1 and 
ERAP2 were incubated with DG057 for 30 min. 
Afterwards, the PLC was incubated for 30 
minutes with either A: ERAP1, ERAP2 or 
ERAP1/ERAP2 only or B: ERAP1, ERAP2 or 
ERAP1/ERAP2 pre-incubated with DG057. 
Additionally, DG057-incubated PLC was 
incubated with ERAP1, ERAP2 or 
ERAP1/ERAP2 mixture. The beads were then 
washed with buffer and bound proteins eluted 
and analyzed on SDS-PAGE (Figure 8B). All 
components of the PLC were detected bound 
onto the streptavidin beads, but neither ERAP1 
nor ERAP2 were found in the pulldown. In 
contrast, ERAP1 and ERAP2 were only detected 
in the wash fraction (supernatant). SEC analysis 
of the same conditions confirmed this result. The 
migration behavior of the PLC or ERAP1/2 was 
not altered after peptide incubation and 
treatment with ERAP1 (Figure 8C), ERAP2 
(Figure 8D), or ERAP1/2 mixture (Figure 8E). 
Also, the addition of DG057 did not alter the 
migration behavior of any of the protein 
components. This analysis suggests that even in 
the presence of a non-hydrolysable peptide 
analogue trap for ERAP1 or 2, no stable 
molecular complex between ERAP1 or ERAP2 
and the PLC could be detected.  
 
Discussion 
 
 A detailed understanding of how 
ERAP1 trims antigenic peptide precursors is 
potentially of critical significance as it can alter 
our understanding of the generation of the 
cellular immunopeptidome. Several studies have 
already demonstrated significant effects of 
ERAP1 down-regulation on the 
immunopeptidome of cells and have associated 
these changes with alterations of adaptive 
immune responses in autoimmunity and cancer 
(13). Furthermore, pharmacological regulation 
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 8 
of ERAP1 activity is an emerging approach for 
cancer immunotherapy and thus a deep 
mechanistic knowledge on how ERAP1 
regulates the immunopeptidome is crucial for 
optimizing potential therapies (46) (47).  
 Two main pathways of ERAP1-
mediated antigenic peptide generation have been 
proposed in the literature (26). In one, solution 
trimming of antigenic peptide precursors 
precedes MHCI loading, while in the second, 
peptides are first bound onto MHCI and are then 
trimmed by ERAP1. For the second pathway, 
two distinct sub-mechanisms can be envisaged: 
i) ERAP1 trims peptides that overhang away 
from the MHCI without any atomic interactions 
with the MHCI and ii) ERAP1 trims peptides 
while making specific atomic interactions with 
the MHCI that help orient it towards the peptide 
and guide trimming. While these pathways and 
mechanisms are not mutually exclusive, they 
present key differences on how ERAP1 
recognizes and selects its substrates. Solution 
trimming, as a well-established mechanism for 
M1 aminopeptidases, requires enzyme-peptide 
interactions between the N-terminus of the 
peptide and the active site, which in the case of 
ERAP1, may extend to the whole length of the 
peptide (18,21). Indeed, recent high-resolution 
crystal structures of ERAP1 with peptide 
analogues revealed extensive interactions 
between the peptide and a large internal cavity in 
the enzyme where the substrate is sequestered 
during the catalytic cycle (19,48,49). In addition, 
a specific interaction between the C terminus of 
the peptide and a regulatory site of ERAP1 was 
found to be important for longer peptides (49). 
In contrast, on-MHCI trimming necessitates that 
at least some interactions remain between MHCI 
and the peptide, at the minimum between the C-
terminus of the peptide and the F-pocket of the 
MHCI antigen binding groove (31). 
Additionally, loss of ERAP1-peptide 
interactions may be substituted with 
ERAP1/MHCI interactions that could enhance 
peptide trimming rates. While most 
MHCI/peptide crystal structures known to date 
have the peptide N-terminus tightly bound to the 
MHCI, some notable exceptions exist, which 
demonstrate how the peptide N-terminus can 
extend away from the MHCI and thus be 
vulnerable to trimming by an aminopeptidase 
(33,50). This was recently demonstrated with a 
series of extended peptides bound onto HLA-
B08 (37). In contrast, formation of a transient 
ERAP1/MHCI trimming complex would 
necessitate conformations not before observed 
experimentally, but simulated computationally 
(31,51). To date, no direct ERAP1/MHCI 
protein-protein interactions have been 
demonstrated (26). 
 Here, we investigated ERAP1-mediated 
trimming in different cases of antigenic peptide 
precursors in solution and in complex with 
MHCI alleles HLA-B*58, HLA-B*08 and HLA-
A*02. We tested peptides in MHC complexes 
where both of the peptide termini are buried 
within the binding groove, peptides that have 
different length central bulges and peptides in 
MHCI complexes where the N-termini extends 
away from the groove at variable lengths. Our 
aim was, on the one hand, to test the generality 
of previous studies that suggested on-MHC 
trimming (23,31), and on the other hand, to test 
the relative kinetics of the two mechanisms, 
something that has not been addressed before. 
Kinetic analysis is critical to a detailed 
understanding of enzyme function, given that 
rates will determine whether a particular reaction 
is relevant in a biochemical pathway. We find 
that in all cases tested (11 different peptide 
sequences and their various length variants, and 
3 HLA alleles), MHCI binding protects rather 
than facilitates ERAP1 trimming, similar to what 
was demonstrated before for a murine MHCI 
(30). Of the antigenic peptide precursors tested, 
only one 12mer, which when bound to HLA-
B*08, was found to be trimmed at apparent rates 
that were within the same order of magnitude as 
solution trimming. This was in sharp contrast to 
another 12mer what when bound to the same 
allele was completely protected from ERAP1. 
Biophysical analysis suggested that these two 
12mers differ greatly in thermodynamic stability 
and that the 12mer that was susceptible to 
ERAP1, is very labile and can rapidly dissociate 
from MHCI, at rates faster than the fastest 
recorded rate of ERAP1 trimming for this 
peptide. Indeed, on-MHCI trimming for this 
peptide was in all cases slower than the 
dissociation rate, suggesting that the observed 
trimming could be explained by a two-step 
mechanism that depends on rapid dissociation 
and subsequent solution trimming steps. This 
would suggest that previous observations of 
apparent on-MHC trimming were limited to the 
particular combination of MHCI allele / peptide 
tested and were likely due to the dynamic nature 
of the peptide-MHCI complex rather than a 
specific ERAP1/MHCI interaction. 
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 Although ERAP1 has been extensively 
studied for its ability to generate antigenic 
peptides from N-terminally elongated 
precursors, it can also over-trim antigenic 
peptides to lengths not suitable for binding onto 
MHCI, essentially destroying the epitope (3). 
Recent analysis on the effect of ERAP1 on the 
immunopeptidome of cells have suggested that 
the destructive properties of ERAP1 may have 
been underestimated and could actually be the 
dominant function of the enzyme (47,52,53). 
The data presented herein highlight the ability of 
MHCI to protect peptides from ERAP1-
mediated degradation and are thus consistent 
with the hypothesis that ERAP1 acts to limit 
available peptides for MHCI. 
 Since the discovery of ERAP1, several 
studies have recognized its specialized function 
in processing antigenic peptides (54). Indeed, in 
vitro analyses have revealed that ERAP1 like 
other related aminopeptidases has preferences 
for the peptide N terminus (55,56) but, unlike 
other related aminopeptidases it also has 
preferences for peptide length and sequence 
(18,20,21), including the C terminus of the 
peptide (21). Recently solved high-resolution 
crystal structures of ERAP1 with peptide 
analogues have provided insight on the atomic 
basis of these properties by identifying a 
regulatory site that is responsible for recognition 
of the C terminus of elongated peptides(49). The 
homologous ERAP2 does not share the length 
preferences and C-terminal recognition 
properties of ERAP1, consistent with a discrete 
role in antigen processing (38,40). Additionally, 
LAP does not have any length or internal 
sequence preferences (20). Therefore, if the 
primary mechanism of ERAP1-mediated 
trimming included the recognition of the 
MHCI/peptide complex as a substrate, one might 
expect ERAP1 to be especially efficient in 
trimming peptides bound onto MHCI. We find 
no evidence for this however since, in all cases 
tested, binding of a peptide onto MHCI protected 
it from ERAP1 activity. Furthermore, ERAP2 
and the unrelated aminopeptidase LAP, appear 
to be just as efficient in trimming a 12mer 
peptide (AI12) in preformed complexes with 
B08. This finding suggests that the apparent 
trimming of AI12 is rather due to the properties 
of the B08/AI12 complex rather than the 
aminopeptidase used. In fact, fast dissociation of 
AI12 and subsequent solution trimming, is the 
simplest possible model that can account for 
these observations. Furthermore, specialization 
for trimming of peptides bound onto MHC 
would necessitate some sort of interaction 
between ERAP1 and MHCI. While this 
interaction could be expected to be transient due 
to the nature of the enzymatic reaction, it should 
be stabilized using transition-state analogue 
substrates as demonstrated previously (40,49). 
However, our analysis failed to demonstrate the 
existence of a ternary ERAP1/peptide/MHCI 
complex, while the binary ERAP1/peptide and 
MHCI/peptide complexes could be detected. 
This finding suggests that ERAP1 cannot 
directly access the N terminus of a 12mer peptide 
that is bound onto MHCI, at least under the 
experimental conditions tested here. 
 A recent study demonstrated ERAP1-
mediated peptide trimming of a 16mer peptide 
that was anchored onto the MHCI via a disulfide 
bond near its C-terminus (23). In this case, 
ERAP1 trimming cannot possibly follow peptide 
full dissociation since the peptide is covalently 
bound onto the MHCI, but the peptide N-
terminus could transiently detach from the A-
pocket and extend away from the MHCI as 
previously modelled (31). A long overhang 
could be structurally consistent with ERAP1 
trimming, but steric hindrance and lack of 
activation by the regulatory site should make 
trimming less efficient. Indeed, in a recent study, 
the authors had to use a 100-fold higher 
concentration of ERAP1 to achieve similar 
trimming of the peptide-MHCI compared to the 
peptide in solution (37). Therefore, even in that 
case, MHCI binding protected, rather than 
promoted, peptide trimming.  
 As with any in vitro study, our study’s 
conclusions are limited to the components of the 
in vitro system used. In particular, given that 
inside the cell, MHCI loading is facilitated by the 
PLC it is conceivable that the PLC could 
facilitate, or even mediate, an ERAP1/MHCI 
interaction that could drive on-MHCI trimming 
in cells (57). Such an interaction, however, has 
not been demonstrated yet, and structural 
analysis of the PLC has suggested that it is 
topologically unlikely (29). Accordingly, and 
despite our efforts, we were unable to 
demonstrate any molecular interaction between 
cell-purified PLC and ERAP1 or ERAP2, even 
when using a N-terminally extended antigenic 
peptide that carried a transition state analogue N-
terminus optimized to have high affinity for 
ERAP1. This result, agrees well with the rest of 
our observations that suggest that antigenic 
peptide precursor trimming by ERAP1 takes 
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on A
pril 13, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 10 
place in solution, without the peptide having any 
significant and/or stable interactions with the 
MHCI binding groove.   
 In summary, we performed a thorough 
comparison of peptide trimming by ERAP1, in 
solution and in pre-formed complexes with 
MHCI. We find that solution trimming is always 
faster than for pre-formed MHCI-peptide 
complexes, and that in all cases MHCI binding 
protects the peptide from ERAP1 trimming. 
Furthermore, we demonstrate that when 
apparent on-MHC trimming is observed, it is 
limited by the peptide’s dissociation kinetics and 
we could find no evidence for any 
ERAP1/MHCI interaction, even within the 
context of native PLC. Thus, we propose that 
ERAP1-mediated antigenic peptide processing, 
even when demonstrated using pre-formed 
MHCI-peptide complexes, can be fully 
explained by well-established properties of 
components of the system: i) the ability of 
ERAP1 to trim peptides in solution and ii) the 
dynamic binding of peptides onto MHCI (58). 
We conclude that with current evidence, there is 
no reason to adopt more auxiliary trimming 
modes that involve on-MHCI trimming and that 
the well-established solution trimming is 
sufficient to explain experimental observations 
(26). 
 
Experimental Procedures 
 
HLA-B*08:01 and β2m expression and 
purification: Both the HLA-B*08:01 heavy 
chain and beta-2 microglobulin were expressed 
as inclusion bodies in Escherichia coli BL21 
DE3 cells, induced at OD600 of 0.8 with 1 mM 
isopropyl-1-thio-D-galactopyranoside (IPTG, 
AppliChem-A4773). Cells were harvested after 
4 h by centrifugation (4.000 g, 15 °C, 15 mins). 
Cells were disrupted both by enzymatic lysis 
with lysozyme (AppliChem-A3711, 1 mg/mL 
suspension) and osmotic shock by sucrose (BDH 
Laboratory Supplies) solution [25% w/v sucrose, 
50 mM Tris-HCl pH 8, 1 mM EDTA (PanReac  
Quimica-A5097) and 0.1% w/v NaN3 (Sigma 
Aldrich-S2002)] and deoxycholic acid (Fisher 
Scientific-BP349100) solution [1% w/v 
deoxycholic acid, 1% v/v Triton X-100 (Fisher 
Scientific - BP151-100), 20 mM Tris-HCl pH 8, 
100 mM NaCl (AppliChem-A2942) and 0.1% 
w/v NaN3]. DNase (Sigma Aldrich-DN25) and 
MgCl2 (Sigma Aldrich-M2670) were added at a 
final concentration of 10 µg/mL suspension and 
5 mM, respectively. The pellet was then 
subjected to 3 subsequent washes (after each 
wash pellet was centrifuged at 8.000 g, 4 °C, 20 
min) with Triton X-100 solution (0.5% w/v 
Triton X-100, 50 mM Tris-ΗCl pH 8, 100 mM 
NaCl, 1 mM EDTA and 0.1% w/v NaN3) 
followed by 3 subsequent washes with Tris-HCl 
(Tris Ultrapure from AppliChem-A1086, 
Hydrochloric Acid from AppliChem-AL1021) 
solution (50 mM Tris-HCl pH 8, 1 mM EDTA 
and 0.1% w/v NaN3). Finally, inclusion bodies 
were solubilized using Urea (Applichem-
A8113) solution [8 M urea, 25 mM MES (Sigma 
Aldrich-M3671) pH 6 and 10 mM EDTA] and 
stored at -80°C until needed. 
HLA-A*02:01 expression and purification: 
HLA-A*02 heavy chain was expressed as 
inclusion bodies in Escherichia coli strain XL-1 
Blue cells without induction. Single colony from 
LB agar Petri dishes (Agar molecular biology 
grade from AppliChem-A3477) was inoculated 
at 2 mL LB broth (1% w/v Tryptone Biochemica 
from AppliChem-A1553, 0.5% w/v yeast extract 
for molecular biology from AppliChem-A3732, 
0.5% NaCl, 1% glucose from PanReac Quimica-
A3666) containing 100 µg/mL ampicillin for 8 h 
at 37 °C. Afterwards, cell culture was transferred 
to a flask containing 200 mL LB broth and 100 
µg/mL ampicillin (AppliChem-A0839). 
Incubation followed for 20 h at 37 °C. 
Subsequently, cells were harvested by 
centrifugation (4.000 g, 15 °C, 15 mins). 
Purification was conducted by the same 
procedure which was followed for ΗLA-
B*08:01 heavy chain and b2 microglobulin. 
Expression and purification of HLA-B*58:01: 
HLA-B*5801 was expressed in BL21(DE3) 
cells harboring the HLA-B*5801/pET22b(+) 
expression plasmid (33). E. coli cells at 0.6-0.8 
OD600, were induced with 1mM IPTG for 4 h at 
37 ̊C for the expression of HLA-B*5801 
inclusion bodies. Cells were harvested at 4000 
rpm after induction and were resuspended in the 
extraction buffer (50 mM Tris-HCl, 100 mM 
NaCl, 10 mM MgCl2, 1% Triton-X100, pH 8.2) 
with freshly added lysozyme (2mg/mL), DNase 
and PMSF (1mM). Cells in extraction buffer 
were sonicated and inclusion bodies were 
collected at 8000 rpm for 30 min. Inclusion 
bodies were again resuspended in the same 
buffer and the above step is repeated to 
efficiently lyse cells and for a pure preparation 
of inclusion bodies. The inclusion bodies were 
washed thrice with wash buffer (50 mM Tris, 
20mM EDTA, pH 8.0) to remove detergent and 
other soluble proteins. Purified inclusion bodies 
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were resuspended in 8M Urea and stored at -80 
 ̊C. 
Expression and purification of ERAP1 and 
ERAP2: High-five (Hi5) insect cells were 
grown in Sf-900II culture medium 
(ThermoFisher Scientific-12658019) at 27 °C. 
Infection with recombinant baculovirus was 
carried out in 50 mL flasks at a cell density of 1 
to 1.5 × 106 cells/mL and incubation continued 
by gentle shaking at 27 °C for 72 h. The culture 
medium was centrifuged (4500 g, 15 min, 4 °C) 
and the supernatant was dialyzed overnight 
against buffer containing 10 mM NaH2PO4 
(Sigma Aldrich-04269) adjusted to pH 8 with 
NaOH (Merck-S8045) and 100 mM NaCl. 
Supernatant was then equilibrated to binding 
buffer (50 mM NaH2PO4 pH 8, 300 mM NaCl 
and 10 mM imidazole). Batch binding onto Ni-
NTA Agarose beads (ThermoFisher Scientific-
R90101) was achieved by mild rotation at 4 °C 
for 2 h. Supernatant and beads were afterwards 
loaded to Ni-NTA column and washed several 
times with buffer: 50 mM NaH2PO4 pH 8, 300 
mM NaCl and 10-30 mM imidazole 
(AppliChem-A3635). Elution was performed by  
50 mM NaH2PO4 pH 8, 300 mM NaCl and 150 
mM imidazole. Final dialysis of elution fractions 
was conducted overnight against 10 mM Hepes 
(Sigma Aldrich-54457) pH 7 and 100 mM NaCl. 
Protein aliquots were kept at -80°C after addition 
of 10% v/v glycerol (Sigma Aldrich-G5516). 
Purification of Peptide Loading Complex 
from Raji cells: The Peptide Loading Complex 
was purified from Raji cells with all of its 
components (TAP1/2, ERp57, Calreticulin, 
Tapasin and HLA-A*03) utilizing the 
herpesvirus I TAP inhibitor ICP47 equipped 
with a SBP tag (ICP-SBP) as previously 
described (29).  
Peptide Loading Complex pulldown assay: 
Purified PLC was bound on high capacity 
streptavidin agarose beads (Pierce) after 
purification from Raji cells and incubated for 30 
min, 4°C on an overhead rotor with 4-fold excess 
of either DG057, ERAP1, ERAP2 or a mixture 
ERAP1/ERAP2. In addition, ERAP1, ERAP2 or 
ERAP1/ERAP2 were incubated for 30 min with 
equimolar ratios of DG057 before incubation 
with the PLC for 30 min, 4°C on an overhead 
rotor. The supernatant was collected, and the 
beads washed three times with buffer (20 mM 
Hepes pH 7.5, 150 mM NaCl, 0.02 % GDN, 1.25 
mM benzamidine, 0.5 mM PMSF). The PLC 
was eluted by boiling in 5x SDS-PAGE loading 
buffer. Protein pulldown was analysed by SDS-
PAGE (4-12 % Bis-Tris gels, NuPAGE™, 
stained by InstantBlue™). 
Peptide Loading Complex ERAP1/ERAP2 
size exclusion analysis: 3.5 pmol of purified 
PLC were incubated with ERAP1, ERAP2, or 
ERAP1/2 mixtures in the presence or absence of 
DG057 as described above for 30 min at 4°C, 
respectively. SEC analysis was performed with a 
Shimadzu HPLC system equipped with a 
Shodex KW404-4F column in running buffer 
(20 mM Hepes pH 7.5, 150 mM NaCl, 0.01 % 
GDN). 
Folding of HLA-B*58:01: HLA-B*58:01 (56 
mg), β2m (28 mg) and dipeptide GF (200 mg) 
was diluted in 100 mM Tris-HCl pH 8.0, 0.4 M 
arginine, 0.5 mM oxidized glutathione, 1.5 mM 
reduced glutathione, 2 mM EDTA, 4 M urea, 0.2 
mM PMSF, 1X protease inhibitor cocktail in a 
volume of 500 mL and kept at 4 °C for 2 hours 
on stirring. After 2 hours, peptide was added 
(TW10 or its variants) (3µM) and the mixture 
left at 4 °C for 24 hours while stirring.  The 
folding solution was then dialyzed for 4 h against 
0.1 M urea, 10 mM Tris-HCl pH 8.0, and for 
another 40 hours against 10 mM Tris-HCl pH 8.0 
at 4 °C. After dialysis, the folding mixture was 
filtered and concentrated for purification on a 
Superdex 200 gel filtration column 
preequilibrated in phosphate buffered saline 
(PBS). 
Folding of ΗLA-B*08:01 and ΗLA-A*02:01: 
Protein complexes were folded in vitro from urea 
solubilized inclusion bodies of heavy chain (1 
µΜ) and b2m (2 µΜ) in presence of peptide 
(GeneCust and JPT Peptide Technologies) in 
excess (40 μΜ). Peptides were dissolved in 
DMSO (MP Biomedicals-MFCD00002089). 
The complexes were reconstituted in folding 
buffer which contained 0.4 M arginine 
(AppliChem-A3675), 100 mM Tris-HCl pH 8, 2 
mM EDTA, 5% v/v glycerol, 5 mM reduced 
glutathione (AppliChem-A2084), 0.5 mM L-
glutathione oxidized (Acros Organics-
320220050) and 0.1 mΜ PMSF (AppliChem-
A0999). Complexes were purified by size 
exclusion chromatography in Sephacryl S-200 
High Resolution column using buffer containing 
150 mM NaCl and 10 mM Tris-HCl pH 8. 
Purified complexes were concentrated to 8-12 
μΜ and kept at -80°C after addition of 10% v/v 
glycerol. 
Differential Scanning Fluorimetry assay 
(DSF): The assay was performed in the 
LightCycler 96 RT-PCR instrument (Roche). 
Reaction mixtures (total volume 20 μL) 
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consisted of 16 μL protein complex (final 
concentration 8 μΜ) and 4 μL of 50X SYPRO-
Orange (Sigma Aldrich-S5692) dye (stock 
solution of 5000X was diluted in 10 mM Tris-
HCl pH 8, 150 mM NaCl). Excitation 
wavelength was set at 533 nm and emission 
wavelength at 572 nm. A temperature gradient 
from 25 ˚C to 80 ˚C at a rate of 0.02 ˚C/sec was 
used to generate the denaturation curves. The 
denaturation curves were plotted as fluorescence 
intensity versus temperature and first derivative 
curves were generated using the LightCycler 96 
1.1 software. The minimum point of the first 
derivative of each curve provided the melting 
temperature (Tm). 
Thermal stability evaluation by circular 
dichroism: CD spectra were acquired using a 
Jasco J-715 instrument equipped with a PTC-
348 temperature control unit. Temperature was 
increased from 20 ˚C to 90 ˚C at 1 ˚C/min and 
data points were acquired every 0.2 ˚C by 
monitoring a wavelength of 230 nm. The assay 
was performed using 120 μL of protein complex 
at 8-10 μM. Data were fitted to a sigmoidal 
Boltzmann equation using GraphPad Prism. 
Peptide dissociation followed by SYPRO-
ORANGE: The assay was performed in the 
Lightcycler 96 RT-PCR instrument. Reaction 
mixtures (total volume 20 μL) consisted of 16 μL 
protein complex (final concentration 8 μΜ) and 
4 μL of 50X Sypro Orange dye. Excitation 
wavelength was set at 533 nm and emission at 
572 nm. The temperature was set at 37 ˚C for the 
duration of the experiment. Data were fit to a 
one-phase decay model using GraphPad Prism. 
For HLA-B*58 complexes, differential scanning 
fluorimetry (DSF) was performed on Bio-RAD 
C1000 thermal cycler RT-PCR under the FRET 
channel. Reactions mix contained 10µM HLA-
B58-peptide complexes and 10X (v/v) SYPRO 
orange (Invitrogen) in 20µl volume in PBS in 
96-well plates. For thermal stability 
measurements, the temperature scan rate was 1 
°C/min and temperature range scanned was 20-
95 ˚C. For calculating Tm values, rfu values 
obtained for different complexes at different 
temperature were normalized to calculate 
percent protein folded or unfolded and 
normalized values were fit to Cumulative-
Gaussian percentages. For more detailed 
analysis, the temperature derivative of the 
melting curve was computed and was plotted. 
The data were plotted on GraphPad Prism 7. For 
kinetic measurements, 10µM B58 complexes 
were incubated with 10X SYPRO orange with 
fluorescence measured after every 5min. The 
data were fit to one-phase exponential function 
to calculate the half-lives of class I MHC. 
Kinetic competition assays followed by 
native-PAGE: ΗLA-B*0801 complexes with 
12mer peptides LL12 and AI12 were incubated 
with 10-fold higher concentration (100 μΜ) of 
the high affinity peptide ALRSRYWAI at 37 ˚C 
(total reaction volume 50 µL). After incubation, 
samples were immediately subjected to Native 
PAGE analysis. ΗLA-B*0801 complexes with 
12mer peptides LL12 and AI12 were also 
incubated with either ERAP1 or ERAP2 at 
various concentrations (2-100 nM). After 
incubation, samples were collected, 100 μM of 
L-Leucinethiol (Sigma Aldrich-L8397) were 
added and samples were immediately subjected 
to Native PAGE analysis. 
Peptide trimming followed by HPLC: TW10 
peptide variants (11-25mers, 10µM) or HLA-
B*58 folded with N-extended peptides (10 µM) 
were incubated with ERAP1 (20 or 100nM) at 
room temperature in 20 mM Tris-HCl, pH 7.5, 
100mM NaCl. The reactions at different time 
points (0-120min) were terminated by adding 
0.1% (v/v) trifluoroacetic acid (TFA). Quenched 
reaction mixtures were analyzed on C18-RP-
HPLC using acetonitrile gradient (20-40%) in 
0.05% (v/v) TFA. The percentage of the 
substrate peptide left after hydrolysis was 
calculated by integration of the area under each 
peptide peak. Data were plotted on GraphPad 
Prism 7. 
Peptide trimming assay followed by MALDI 
TOF-MS: Peptides or MHCI/peptide complexes 
were diluted to 10 μM in buffer containing 10 
mM Tris-HCl pH 8, 150 mM NaCl. Total 
reaction volume was 50 μL. Aminopeptidases 
(ERAP1, ERAP2 or LAP) were added at various 
final concentrations (from 2 to 100 nM) and the 
mixtures were incubated at 37 ˚C. Reactions 
were quenched by adding TFA (AppliChem-
A0697) to a 1 % final concentration and stored 
at -80 ˚C until ready to analyze. For analysis, 
samples were diluted 1:10 with matrix solution 
[7mg/mL alpha-Cyano-4-hydroxycinnamic acid 
in 50% Acetonitrile (AppliChem-131881), 0.1% 
TFA] and spotted on a stainless steel MALDI 
target using the dried droplet method. Peptide 
masses were determined by MALDI-TOF/TOF 
MS (Ultraflex TOF/TOF, Bruker Daltonics, 
Bremen, Germany), peak list was created with 
Flexanalysis v3.3 software (Bruker), smoothing 
was applied with Savitzky-Golay algorithm 
(width 0.2 m/z, cycle number 1), and a 
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Signal/noise threshold ratio of 2.5 was allowed. 
10 x 1000 shots per spectrum were acquired at a 
laser frequency of 500 Hz. The instrument was 
operated in reflector mode with matrix 
suspension set to 600 m/z. Spectra were acquired 
in positive ion mode in the range of 750-3500 
m/z. All spectra and respective peak lists were 
exported with Flexanalysis v3.3. 
Fluorigenic enzymatic assay: Measurements 
were performed using a Spark 10M (TECAN) 
multimode microplate reader. The fluorescent 
substrate Leucine-aminomethylcoumarine (L-
AMC, Sigma Aldrich-L2145) was used for 
ERAP1 and Leucine Aminopeptidase (LAP, 
Sigma Aldrich-L5006) and Arginine-
aminomethylcoumarine (R-AMC, Sigma 
Aldrich-A2027) was used for ERAP2. 
Excitation was adjusted at 380 nm and emission 
at 460 nm. The reaction was performed in 50 
mM Hepes pH 7, 100 mM NaCl with 100 μM of 
substrate in a total volume of 150 μL. Enzyme 
final concentration was 10 nM for ERAP1, 2 nM 
for ERAP2 and 3 nM for LAP. Increasing 
concentrations of DG078 phosphinic peptide 
(either in solution or in complex with 
HLA*B0801) were added at the start of the 
reaction. The IC50 of DG078 inhibitor was 
calculated by using the equation log (inhibitor) 
vs. response-variable slope using GraphPad 
Prism. 
Synthesis of pseudophosphinic peptides 
DG078 and DG057: 
Phosphinic peptide DG078 {H-
AΨ[P(O)(OH)CH2]KAALRSRYWAI-OH} and 
DG057 {H-
hFΨ[P(O)(OH)CH2]GGSGSGSQFGGGSQY-
OH} were prepared by applying standard solid-
phase peptide synthesis, on trityl alcohol lanterns 
(15 μmol/pin) using a Fmoc chemical protocol 
(Supporting Figure 17). Trityl alcohol lanterns 
were converted to the corresponding trityl 
chloride by using a solution of acetyl chloride in 
dry dichloromethane (1:10 v/v) at room 
temperature. For DG078, Fmoc-Ile-OH (30 
μmol/pin), the first aminoacid of the sequence, 
was attached on trityl chloride lanterns by using 
N,N-diisopropylethylamine (18 μL/pin) in dry 
dichloromethane (0.4 mL/pin) at room 
temperature for 12 h (59,60). The loading 
amount of Fmoc-Ile-OH was estimated to be 
13.6 μmol/pin, after removal with 0.5 % 
trifluoroacetic acid (TFA)/dichloromethane 
(room temperature, 1h) from the polymer-
support. In a similar manner, the first aminoacid 
for the synthesis of DG057, Fmoc-Tyr(tBu)-OH, 
was coupled with a loading of 11.1 μmol/pin. In 
both peptides, Fmoc deprotection was achieved 
by soaking the lanterns into a solution of 20% 
piperidine in N,N-dimethylformamide over 1h 
for each cycle of the synthesis. Fmoc protected 
aminoacids (45 μmol/pin) were coupled to the 
developing peptide by using 1-
hydroxybenzotriazole (45 μmol/pin) and N,N-
diisopropylcarbodiimide (45 μmol/pin) in 
dichloromethane/N,N-dimethylformamide (6/1) 
(0.4 ml/pin), were used for the coupling steps 
and each coupling reaction was allowed to 
proceed for 5h. For DG078, in order to avoid 
incomplete couplings during the introduction of 
5th and 7th aminoacids (both Arg), DMF was 
replaced by NMP and the mixture was sonicated 
at 50 ˚ C for 3-4h. No deviation from the standard 
protocol was necessary for the synthesis of 
DG057.  Side-chain protected aminoacids that 
were used are: Fmoc-Tyr(tBu)-OH, , Fmoc-
Gln(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-
Trp(Boc)-OH and Fmoc-Arg(Pbf)-OH. 
Coupling of the building block Boc-(R)-
Ala[PO(OAd)-CH2]-(R,S)-Lys(Boc)OH (23 
μmol/pin) and Boc-(R)-hPhe[PO(OAd)-CH2]-
GlyOH (23 μmol/pin), for DG078 and DG057 
respectively, was performed using the coupling 
conditions described above (36 μmol/pin of each 
reagent). Deprotection and removal of the final 
pseudopeptides from the polymer support was 
accomplished by using a solution of 
trifluoroacetic acid 
(TFA)/dichloromethane/triisopropylsilane/H2O 
39/58/2/1 for 3h at room temperature. After 
concentration in vacuo, the crude products were 
precipitated in cold diethyl ether. DG078 and 
DG057 were obtained after purification by 
analytical reverse-phase HPLC and 
characterized by mass spectroscopy. DG078: 
electrospray–mass spectrometry m/z (z = 1): 
calculated for [C65H106Ν19Ο16P+H]+ 
1439.78; found: 1440.79; DG057: electrospray–
mass spectrometry m/z (z = 1): calculated for 
[C64H90Ν17Ο25P+H]+ 1528.6; found: 
1528.5]. 
Synthesis of Boc-(R)-Ala[PO(OAd)-CH2]-
(R,S)-Lys(Boc)OH: For the synthesis of 
building block Boc-(R)-Ala[PO(OAd)-CH2]-
(R,S)-Lys(Boc)OH (6), 4-aminobutanol was 
subjected to Boc-protection and subsequent 
Appel iodination, according to literature 
procedures, to afford iodide 2 in 54% yield for 
the 2 steps (61,62) (Supporting Figure 18). 
Iodide 2 (1.8 g, 6.0 mmol) was dissolved in 28 
mL of 1:1 mixture DMF/toluene, HC(CO2Et)3 
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on A
pril 13, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 14 
(1.53 g 6.6 mmol), K2CO3 (1.08 g, 7.82 mmol) 
was added and the mixture was refluxed for 1 h, 
according to our previously published procedure 
(44). After aqueous workup, the crude product 
was saponified with KOH (10 equiv) in EtOH 
and the resulting diacid was subjected to 
Knoevenagel condensation, affording acrylic 
acid analogue of 3 (887 mg, 61% yield for 3 
steps) (44). The resulting acid (787 mg, 3.23 
mmol) was dissolved in CH2Cl2 (5 mL) and 
benzyl alcohol (350 mg, 3.24 mmol), DCC (801 
mg, 3.89 mmol) and DMAP (40 mg, 0.32 mmol) 
were successively added. After stirring during 5 
h at rt, the mixture was filtrated and the filtrates 
were concentrated, dissolved in Et2O (30 mL) 
and H2O (10mL) and the organic layer was 
washed with 1M HCl (10 mL), 5% NaHCO3 (10 
mL) and brine (5 mL), dried over Na2SO4 and 
concentrated in vacuo. Compound 3 (895 mg, 
83%) was obtained as colorless viscous oil after 
silica gel column chromatography (PE 40−60 
°C/AcOEt 9:1 → 2:1). 1H NMR (200 MHz, 
CDCl3) δ 1.42 (s, 9H), 1.41 – 1.53 (m, 4H), 2.24 
– 2.38 (m, 2H), 3.01 – 3.15 (m, 2H), 4.51 (br s, 
1H), 5.54 (q, J = 1.4 Hz, 1H), 6.15 – 6.21 (m, 
1H), 7.23 – 7.39 (m, 5H); 13C NMR (200 MHz, 
CDCl3) δ 25.6, 28.4, 28.5, 29.6, 31.5, 40.5, 66.4, 
79.2, 125.3, 128.1, 128.2, 128.6, 136.1, 140.3, 
156.1, 167.0. In a mixture of aminophosphinic 
acid 4 (300 mg, 1.44 mmol) and 3 (574 mg, 1.72 
mmol) in CH2Cl2, BSA (1.07 mL, 4.31 mmol) 
and TMSCl (0.55 mL, 4.31 mmol) were added 
under Ar atmosphere at -78oC and the resulting 
mixture was stirred at rt during 5 d. Then, the 
mixture was cooled at 0 °C, EtOH (1.5 mL) was 
slowly added and stirring was continued for 20 
min. After removal of the volatiles in vacuo, the 
residue was taken up by AcOEt (20 mL) and the 
organic solution was washed with 2 M HCl (2 × 
10 mL) and brine (10 mL). The organic layer was 
dried over Na2SO4 and evaporated in vacuo to 
afford the crude product. Compound 5 (490 mg, 
56%) was obtained as a gummy solid after silica 
gel column chromatography 
(CHCl3/MeOH/AcOH 7:0.03:0:03 → 7:0.3:0.3). 
1H NMR (200 MHz, CD3OD) δ 1.28 & 1.32 (2 × 
d, J = 14.5 Hz, 3H), 1.42 & 1.44 (2 × s, 18H), 
1.41 – 2.02 (m, 7H), 2.07 – 2.37 (m, 1H), 2.74 – 
3.05 (m, 3H), 3.78 – 4.00 (m, 1H), 5.08 – 5.24 
(m, 2H), 7.17 – 7.54 (m, 5H); 13C NMR (200 
MHz, CD3OD) δ 13.7, 13.9, 24.9, 25.0, 28.7, 
28.8, 29.2 & 29.4 (2 × d, J = 90 Hz), 34.5, 34.7, 
34.9, 35.1, 40.3, 40.4, 41.0, 45.71 & 46.52 (2 × 
d, J = 107 Hz), 67.59, 79.73, 80.71, 129.2, 129.4, 
129.5, 137.4, 157.4 (d, J = 5.2 Hz), 158.3, 176.1 
(d, J = 6.7 Hz); 31P NMR (81 MHz, CD3OD) δ 
50.3, 50.7. For the preparation of 6, application 
of our previously developed 2-step protocol on 
intermediate 5 (90 mg, 0.17 mmol) involving 
adamantylation of phosphinic acid moiety and 
subsequent removal of benzyl group by 
hydrogenolysis, led to 90 mg of target building 
block 6 (93%, yield for 2 steps) as a mixture of 
4 diastereoisomers. 31P NMR (81 MHz, CD3OD) 
δ 51.9, 52.1, 52.4, 52.6; HRMS (m/z): [M + H]+ 
calcd. for C29H52N2O8P+, 587.3456 found, 
587.3460.     
Molecular Dynamics simulations: The four 
HLA-B8/peptide complexes used for the 
molecular dynamics (MD) study were based on 
the X-ray crystal structure of HLA-B*08:01 
complex with the Influenza A virus 
Nucleoprotein epitope ELRSRYWAI (PDB ID: 
5WMQ)(42), hereafter called HLA-B08/EI9. 
Side-chain atoms in residues with alternative 
conformation B were removed and protonation 
states of histidine residues were estimated using 
H++ server at the experimental pH value of 6.5, 
ionic strength of 0.15 M and default dielectric 
constants (63). The second system, HLA-
B*08:01 in complex with ALRSRYWAI (HLA-
B08/AI9) was produced from the X-ray-based 
model by removing the side-chain atoms except 
Cβ of Glu(P1) residue of EI9. Modeling of the 
extended 12mer peptides ARAALRSRYWAI 
(AI12) and LSILLKHKKAAL (LL12) was 
based on the hypothesis that the peptides would 
bulge out to favorably accommodate their N and 
C termini within the binding groove of HLA-
B08. First, we prepared the model of AI12 using 
MODELLER v9.21 and the crystallographic 
coordinates of residues P1 (E) and P4–P9 
(SRYWAI) as template, so as to constraint the 
position of the N-terminus inside pocket-A of the 
HLA-B08. From 100 models that were 
generated, the peptide-binding groove of HLA-
B08 (residues 1–180) with bound AI12 were 
subjected to unrestraint energy minimization 
using AMBER v16 and the ff14SB force-field in 
implicit solvent (Generalized Born OBC model 
gb-5) (64) (65). The lowest potential energy 
structures were visually investigated to select 
five low-energy conformations of AI12 with the 
highest pairwise root-mean-square deviation 
(RMSD), in order to sample the configurational 
space of the HLA-B08/AI12 more efficiently 
from different starting structures (Supporting 
Figure 7). For the modelling of HLA-B08/LL12 
we used the selected five models of AI12 as 
template, with the aim to compare their 
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conformational space with as similar as possible 
initial conditions (Supporting Figure 8). 
Molecular dynamics simulations were 
performed using the GPU-accelerated PMEMD 
module of AMBER v16 (66). All systems have 
been immersed in truncated octahedral pre-
equilibrated water boxes (TIP3P) with a buffer 
distance of 12 Å around the solute atoms. 
Sodium ions were added to neutralize the total 
charge of the systems and ff14SB parameters 
were applied using the LEaP module of AMBER 
(67). The equilibration method of 10 ns and 
simulation parameters were as described in (68). 
After 1 ns equilibration of the systems at 300 K 
under isothermal-isobaric ensemble (NPT) 
conditions, production runs of 500 ns were 
performed in the canonical ensemble (NVT). 
Specifically, 5 sets of MDs for each B08/EI9 and 
B08/AI9 complex were seeded with random 
initial velocities (Supporting Figure 9) and one 
run for each of the 5 initial models with variable 
peptide conformation for B08/AI12 and 
B08/LL12 (Supporting Figure 10), for an 
aggregate simulation time of 2.5 μs for each 
system. Snapshots of the B08/peptide complexes 
were kept every 10 ps and trajectory analysis was 
carried out using the CPPTRAJ module of 
AMBER (69). The atomic root-mean-square 
fluctuations of the Cα atoms of the peptides were 
calculated after RMSD-fitting of the Cα atoms of 
the antigen-binding groove (residues 1–180) of 
the HLA-B08 heavy chain (Supporting Figure 
11). Considering the effect of the initial 
conformation selected for each of the 12mer 
peptide to the results of their fluctuations at the 
timescale of the MDs, we performed 5 additional 
500-ns simulations for each B08/AI12 and 
B08/LL12 complex, both initiated using the 
same conformation that was employed in 
simulations labelled “sim-2” (Supporting 
Figures 9-11). This conformation was selected as 
“sim-2” displayed the lowest RMSD and RMSF 
values for both peptides during the MDs, but in 
particular for the more labile AI12. The results 
of the peptide Cα RMSF values for each of the 
five sets of simulations seeded with different 
initial velocity distributions (labelled as “sim2a–
2e”, Supporting Figure 13A,B) further supported 
our observation that A12 is considerably more 
labile than LL12, irrespective of the initial 
conformation employed in the MDs (Supporting 
Figures 12, 13C,D). Trajectory visualization and 
rendering of the figures was performed using 
VMD v1.9 (70). 
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Figure 1: Trimming of peptides (10µM) in solution and in pre-formed complexes with HLA-B58 (also 
10µM) by 20 nM ERAP1. Top, list of peptides used and their amino acid sequences. Bottom, percent 
remaining peptide after incubation with 20 nM ERAP1 as calculated by HPLC analysis. Top panels 
correspond to peptide in solution, and bottom panels to peptide in pre-formed complex with HLA-B58 
(two replicates indicated by filled and empty circles).  
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Figure 2: Trimming of FK12 and FM15 in solution (top, panels A-C) and in pre-formed complexes 
with A02 (bottom, panels D-F) followed by MALDI-MS.  
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Figure 3: Trimming of LL12 in solution (top) and in pre-formed complexes with HLA-B*08 
(bottom), by ERAP1 and ERAP2. 
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Figure 4: Panel A, trimming of AI12 in solution and in pre-formed complexes with HLA-B08, by 
ERAP1, ERAP2 and LAP followed by MALDI-MS. Panel B, changes in mobility in native-PAGE of 
HLA-B08/12mer peptide complexes upon incubation with ERAP1 or 9mer peptide. Numbers indicate 
incubation time in minutes. Gels are also shown in supporting figure 5 as part of a complete series. 
Panel C, calculated trimming rates 12mer peptide AI12 from panel A. Panel D, calculated peptide 
exchange rates from native-PAGE experiments. 
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Figure 5: Panel A, Tm values of four HLA-B08 complexes calculated by Differential Scanning 
Fluorimetry Assay and Circular Dichroism. Both approaches reveal the same pattern in relative 
thermodynamic stabilities, although absolute values are lower for CD measurements, possibly due to 
slower scanning rates as previously shown (71,72). Panels B-F: Kinetics graphs describing the 
dissociation of bound peptide off of HLA-B08 during competition by the SYPRO-ORANGE dye. Panel 
G, calculated half-lives of dissociation for each peptide. 
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Figure 6: Plots of the root-mean-square fluctuations from the average position of the Cα atoms of the 
peptides EI9, AI9, AL12 and LL12 as calculated from the MD simulations of the B08/peptide 
complexes. The values given for each residue are mean values from five 500-ns MD simulations with 
error bars showing the standard error of the mean. 
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Figure 7: Panel A, dissociation of DG078 from HLA-B08 during competition with SYPRO-ORANGE. 
Panel B, native PAGE analysis of HLA-B08 and ERAP mixtures. Lane 1, 1 μg of B08/AI12 complex; 
Lane 2, 1 μg B08/DG078 complex; Lane 3, 2 μg ERAP1; Lane 4, 1 μg B08/DG078 mixed with 2 μg of 
ERAP1 (1:1 molar ratio); Lane 5, 2 μg ERAP2; Lane 6, 1 μg B08/DG078 mixed with 2 μg of ERAP2 
(1:1 molar ratio). Panels C and D, relative enzymatic activity of ERAP1 (left) and LAP (right) upon 
addition of 500 nM DG078 or HLA-B08/DG078 complex. Panel E, enzymatic activity of ERAP1 or 
LAP upon titration of DG078 of HLA-B08/DG078 complex. Solid lines represent fits to a four-
parameter dose-dependent inhibition model as described in the methods section. 
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Figure 8: Investigation of the molecular interactions between ERAP1 or ERAP2 with fully assembled 
native PLC. Panel A, schematic illustration of ERAP1 or ERAP2 pulldown with PLC (left), DG057 
preloaded PLC (middle), and pulldown of DG057 preloaded ERAP1 or ERAP2 (right). Panel B, SDS-
PAGE analysis of PLC bound onto streptavidin beads incubated with ERAP1, ERAP2, and 
ERAP1/ERAP2 mixture in absence or presence of peptide DG057. Panel C-D, Overlay of 
chromatograms from size exclusion analysis of mixtures of PLC and ERAP1 (Panel C), ERAP2 
(Panel D) and ERAP1/ERAP2 mixture (Panel E) in presence or absence of peptide DG057. The PLC 
elutes as a single monodisperse peak at 2.85 mL and ERAP1 and ERAP2 as single peaks at 3.58 and 
3.53 mL, respectively. ERAP1/ERAP2 mixture elutes at 3.55 mL. Premixing PLC with either ERAP1 
and/or ERAP2 does not significantly change the migration of the PLC or ERAP1/ERAP2. Addition of 
peptide DG057 to ERAP1/ERAP2 and/or the PLC does not significantly change the migration of the 
proteins. 
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